BECTON DICKINSON & CO shareholders Q4 2023

BECTON DICKINSON & CO's ticker is BDX and the CUSIP is 075887109. A total of 37 filers reported holding BECTON DICKINSON & CO in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.4%.

BECTON DICKINSON & CO shareholders Q4 2023
Name	Shares	Value	Weighting ↓
CACTI ASSET MANAGEMENT LLC	194,224	$47,099,320	3.98%
Rempart Asset Management Inc.	76,974	$18,768,570	3.88%
Somerset Trust Co	13,849	$3,376,801	1.48%
First National Bank of Mount Dora, Trust Investment Services	14,655	$3,573,328	0.95%
ST GERMAIN D J CO INC	49,993	$12,189,793	0.64%
PARK NATIONAL CORP /OH/	24,386	$5,946,038	0.24%
Compass Wealth Management LLC	3,266	$796,349	0.22%
First Affirmative Financial Network	1,110	$270,688	0.22%
Czech National Bank	50,810	$12,389,002	0.18%
Bartlett & Co. LLC	43,850	$10,657	0.17%
CANANDAIGUA NATIONAL BANK & TRUST CO	4,247	$1,035,546	0.16%
M&R CAPITAL MANAGEMENT INC	2,433	$593,238	0.15%
Arden Trust Co	4,025	$981,415	0.14%
Curbstone Financial Management Corp	1,908	$465,228	0.11%
DnB Asset Management AS	71,559	$17,448,231	0.09%
Harbour Capital Advisors, LLC	1,310	$315,016	0.09%
General Partner, Inc.	341	$83,688	0.07%
Boltwood Capital Management	862	$210,181	0.07%
Fragasso Group Inc.	2,067	$503,888	0.05%
BEACH INVESTMENT COUNSEL INC/PA	1,520	$371	0.05%

About BECTON DICKINSON & CO

Becton Dickinson & Co. (BD) is a global medical technology company that specializes in the development, manufacturing, and sale of medical devices, instrument systems, and reagents. The company is headquartered in Franklin Lakes, New Jersey, and has operations in over 50 countries worldwide.

BD's products are used in a variety of healthcare settings, including hospitals, clinics, laboratories, and blood banks. The company's portfolio includes products for medication management, infection prevention, diagnostic testing, and surgical procedures.

BD has a strong track record of innovation, with a focus on developing products that improve patient outcomes and reduce healthcare costs. The company invests heavily in research and development, with over 2,000 patents and patent applications worldwide.

In recent years, BD has made several strategic acquisitions to expand its product portfolio and geographic reach. In 2017, the company acquired C.R. Bard, a leading provider of medical devices for vascular, urology, and oncology applications. This acquisition has strengthened BD's position in the global medical technology market and is expected to drive long-term growth.

BD has a strong financial position, with a market capitalization of over $70 billion and a dividend yield of 1.3%. The company has a solid track record of revenue growth and profitability, with a five-year revenue growth rate of 6.5% and a net profit margin of 9.5%.

Overall, BD is a well-established and innovative company with a strong position in the global medical technology market. With a focus on improving patient outcomes and reducing healthcare costs, the company is well-positioned for long-term growth and success.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BECTON DICKINSON & CO's shareholders in Q4 2023. To view BECTON DICKINSON & CO's shareholder history, click here.